Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid‐positive individuals-Reference-Cited by-同舟云学术

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid‐positive individuals

Published:2019-12 Issue:1 Volume:11 Page:679-689
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Author:

Benedet Andréa L.¹²³⁴,Ashton Nicholas J.⁵⁶⁷⁷⁸,Pascoal Tharick A.¹²,Leuzy Antoine⁹¹⁰,Mathotaarachchi Sulantha¹²,Kang Min S.¹²,Therriault Joseph¹²,Savard Melissa¹²,Chamoun Mira¹²,Schöll Michael⁵⁶⁷⁷⁹,Zimmer Eduardo R.¹¹¹²¹³¹⁴,Gauthier Serge¹¹¹²,Labbe Aurélie¹⁵¹⁶,Zetterberg Henrik⁵⁶¹⁷¹⁸¹⁹,Blennow Kaj⁵⁶¹⁷¹⁸,Neto Pedro R.¹²²⁰²¹²²,

Affiliation:

1. Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill UniversityMontrealQuebecCanada

2. Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill UniversityMontrealQCCanada

3. CAPES Foundation, Ministry of Education of BrazilBrasíliaBrazil

4. CAPES Foundation, Ministry of Education of BrazilBrasiliaBrazil

5. Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of GothenburgMölndalSweden

6. Department of Psychiatry and NeurochemistryInstitute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of GothenburgMolndalSweden

7. Wallenberg Centre for Molecular and Translational MedicineUniversity of GothenburgGothenburgSweden

8. King's College London, Institute of PsychiatryPsychology and NeuroscienceMaurice Wohl Institute Clinical Neuroscience InstituteLondonUK

9. Clinical Memory Research UnitDepartment of Clinical Sciences, MalmöLund UniversityLundSweden

10. Clinical Memory Research UnitDepartment of Clinical Sciences, MalmoLund UniversityLundSweden

11. Alzheimer's Disease Research UnitThe McGill University Research Centre for Studies in Aging, Montreal, McGill UniversityMontrealQuebecCanada

12. Alzheimer's Disease Research UnitThe McGill University Research Centre for Studies in Aging, Montreal, McGill UniversityMontrealQCCanada

13. Department of PharmacologyUniversidade Federal do Rio Grande do SulPorto AlegreBrazil

14. Departament of PharmacologyUniversidade Federal do Rio Grande do SulPorto AlegreBrazil

15. Department of Decision SciencesHEC MontrealMontrealQuebecCanada

16. Department of Decision SciencesHEC MontrealMontrealQCCanada

17. Clinical Neurochemistry Laboratory, Sahlgrenska University HospitalMölndalSweden

18. Clinical Neurochemistry Laboratory, Sahlgrenska University HospitalMolndalSweden

19. Department of Neurodegenerative DiseaseUCL Institute of NeurologyQueen SquareLondonUK

20. Montreal Neurological InstituteMontrealQuebecCanada

21. Montreal Neurological InstituteMontrealQCCanada

22. Department of Neurology and NeurosurgeryMcGill UniversityMontrealQuebecCanada

Funder

Alzheimer's Disease Neuroimaging Initiative

National Institutes of Health

U.S. Department of Defense

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

AbbVie

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

BioClinica

Biogen

Bristol-Myers Squibb

Eisai

Eli Lilly and Company

Roche

Genentech

GE Healthcare

H. Lundbeck A/S

Meso Scale Diagnostics

Novartis Pharmaceuticals Corporation

Pfizer

Servier

Takeda Pharmaceutical Company

Canadian Institutes of Health Research

Weston Brain Institute

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Torsten Söderbergs Stiftelse

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul

Vetenskapsrådet

DOD

ADNI

Department of Defense

Araclon Biotech

BioClinica, Inc

Bristol-Myers Squibb Company

CereSpir, Inc

Cogstate

Elan Pharmaceuticals, Inc

EuroImmun

F. Hoffmann-La Roche Ltd

Genentech, Inc

Fujirebio

IXICO Ltd

Janssen Alzheimer Immunotherapy Research & Development, LLC

Johnson & Johnson Pharmaceutical Research & Development LLC

Lumosity

Lundbeck

Merck & Co, Inc

NeuroRx Research

Neurotrack Technologies

Pfizer Inc

Piramal Imaging

Transition Therapeutics

Alzecure

Canadian Consortium of Neurodegeneration in Aging

CAPES

Wallenberg Center for Molecular and Translational Medicine

Torsten Söderberg Foundation

CNPq

FAPERGS

Brazilian National Institute of Science and Technology in Excitotoxicity and Neuroprotection

SESRS–PPSUS

Swedish Research Council

European Research Council

Swedish State Support for Clinical Research

UK Dementia Research Institute

Fonds de la recherche en santé du Québec

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.dadm.2019.08.002

Reference44 articles.

1. NFL is a marker of treatment response in children with SMA treated with nusinersen

2. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

3. High performance plasma amyloid-β biomarkers for Alzheimer’s disease

4. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Utility of Plasma Biomarker Panels in Differential Diagnosis of Alzheimer’s Disease;Journal of Alzheimer's Disease Reports;2024-01-09

2. Serum total tau, neurofilament light, and glial fibrillary acidic protein are associated with mortality in a population study;Journal of the American Geriatrics Society;2023-10-11

3. Plasma neurofilament light and brain volumetric outcomes among middle-aged urban adults;Neurobiology of Aging;2023-09

4. Relationship of plasma biomarkers to digital cognitive tests in alzheimer’s disease;2023-08-22

5. The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease;Brain;2023-08-04